Month: September 2020

Update: Pharmaceutical Mergers and Acquisitions: Will They Drive Growth?
September 17, 2020 Blog Post Snowfish

Mergers and acquisitions are a hot topic in the biopharmaceutical industry. With 2019 setting records in terms of deal value and volume for biopharmaceutical M&A, many question the purpose of these processes. In addition to increasing shareholder value, management pursues mergers and acquisitions for a variety of reasons including innovation, synergy, and portfolio realignment. In
Details

Amarin Decision: A Tragic Loss for Life Science and Patients
September 7, 2020 Blog Post Snowfish

In a relatively quick ruling, one that Amarin expected to occur in Q4 at the earliest, the U.S Court of Appeals for the Federal Circuit in Washington invalidated Amarin’s six patents. Essentially, this upheld the decision by the U.S District Court for the District of Nevada that Amarin’s patents for Vascepa, were a variation of
Details